Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.
Chinese vaccine maker using viral-vector technology, known for its COVID-19 vaccine and meningitis/rabies/Ebola vaccines.
Most of its non-COVID vaccines are sold on China's voluntary market, where people pay themselves via local disease-control centres rather than through state-funded programmes, so uptake depends on marketing and perceived need. COVID vaccine sales were once large but faded after the pandemic peak. This is the Hong Kong line of a dual-listed company.
In one line: China's viral-vector vaccine player.
Moat: narrow (IP / patents, regulatory licence). Proprietary viral-vector platform and China vaccine licences, but demand fell sharply post-pandemic.
Headquarters: Tianjin, China · Founded: 2009 · Employees: 1,134
Size CanSino Biologics (6185.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $1.36B, the 497th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$22.58 on 18 Nov 2026.
Performance Over six months the shares fell 22.9%, against -20.3% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 36.1% over the last twelve months (peer median +20.3%); the operating margin is -4.0% (peer median -295.1%).
Valuation It trades at 60.5× forward earnings against a peer median of 42.5× (3rd most expensive of 7).
Capital Return on invested capital runs 7.2 points below its cost of capital (9.0% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$1.43B | HK$1.15B | HK$894M | HK$381M | HK$1.20B |
| Revenue growth | — | +28% | +134% | -68% | — |
| Gross profit | HK$1.16B | HK$759M | HK$505M | -HK$1.09B | -HK$313M |
| EBITDA | n/a | HK$67.9M | -HK$217M | -HK$2.11B | -HK$1.50B |
| Net income | HK$34.6M | HK$30.2M | -HK$411M | -HK$1.64B | -HK$1.06B |
| Free cash flow | -HK$71.9M | -HK$170M | -HK$639M | -HK$1.72B | -HK$3.22B |
| Capital expenditure | HK$181M | HK$265M | HK$496M | HK$675M | HK$1.21B |
| Total debt | HK$1.09B | HK$1.44B | HK$2.14B | HK$2.97B | HK$3.03B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CanSino Biologics 6185.HK | $1.36B | -23% | +36% | -4% | 60.5× | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | $5.28B | -1% | -28% | -210% | n/a | -6.5% |
| Walvax Biotechnology 300142.SZ | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6185.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -22.9% | -15.3% | 3rd lowest of 21 |
| 6-month return | -22.9% | -20.3% | 8th lowest of 20 |
| Distance from 52-week high | -51.7% | -48.1% | 9th lowest of 21 |
| Revenue growth (TTM) | +36.1% | +20.3% | 8th highest of 19 |
| Operating margin | -4.0% | -295.1% | 3rd highest of 20 |
| Forward P/E | 60.5× | 42.5× | 3rd most expensive of 7 |
| ROIC minus cost of capital | -7.2 pp | -19.2 pp | 3rd highest of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CanSino Biologics 6185.HK | Hong Kong | $1.36B | -23% | +36% | -4% | 60.5× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Hualan Biological Vaccine 301207.SZ | China | $1.25B | -29% | -28% | -7% | 38.6× | 33.2% | -13.1% |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |